Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
Saved in:
| Title: | Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. |
|---|---|
| Authors: | King B; Dermatology Physicians of Connecticut, Fairfield, CT, USA., McMichael A; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Sinclair R; Sinclair Dermatology, Melbourne, VIC, Australia., Vañó-Galvan S; Hair Disorders Unit at Ramón y Cajal University Hospital, IRYCIS, and Pedro Jaén Group Clinic, University of Alcalá, Madrid, Spain., Wolk R; Pfizer Inc., Groton, CT, USA., Woodworth D; Pfizer Inc., Collegeville, PA, USA., Soma K; Pfizer Inc., Groton, CT, USA., Robbana F; Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, H9J 2M5, Canada. Feriel.Robbana@pfizer.com., Lejeune A; Pfizer Inc., Paris, France., Napatalung L; Pfizer Inc., New York, NY, USA.; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Law E; Pfizer Inc., New York, NY, USA., Wajsbrot D; Pfizer Inc., Groton, CT, USA., Wang C; Pfizer Inc., Groton, CT, USA., Roychoudhury S; Pfizer Inc., New York, NY, USA. |
| Source: | Dermatology and therapy [Dermatol Ther (Heidelb)] 2025 Dec; Vol. 15 (12), pp. 3793-3803. Date of Electronic Publication: 2025 Oct 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
